India will soon start trials to test the safety, immunogenicity and efficacy after mixing doses of different brands of Covid-19 vaccines, reported The Tiimes of India on Tuesday.

The trials will currently include Covaxin, Covishield and Sputnik-V, which currently have emergency use authorisation in the country, going forward the trials may also include jabs that are in the pipeline, senior officials said.

Some studies in the UK and Spain have shown mixing of Pfizer and AstraZeneca vaccines to be safe and immunogenic. However, officials in India maintain that though the concept is scientifically feasible, it cannot be allowed without adequate evidence and therefore, a study has to be conducted.

Also read: India's COVID-19 tally reaches 28,175,044 with 127,510 new cases

The Indian Council of Medical Research, along with the Chennai-based National Institute of Epidemiology, has launched a nationwide study to determine vaccine effectiveness in preventing severe Covid-19 infection. The study will be carried out at 11 sites across 10 cities. A senior scientist with the

 “It is scientifically possible and it is a good thing, especially in a country like ours, such a thing (mixing of doses) will really help boost the vaccination programme. But it is currently not allowed under the vaccination protocol and there is no question of allowing it to happen without adequate evidence generated through trials. Therefore, we have decided to have studies to test the same,” a senior official said.

The decision has also been endorsed by the National Technical Advisory Group on Immunisation (NTAGI). The study — expected to start soon and likely to take about two months — will be conducted by the government in collaboration with vaccine manufacturers.

Also readIndia fought first wave of Covid-19 courageously, will be victorious in second round: PM Modi: 

Jabs for all by December, says govt as Supreme Court quizzes it on vaccine policy

The Centre on Monday told the Supreme Court that it expects the country's entire population above 18 years to be vaccinated against Covid-19 by the end of the year, but the court remained sceptical of the claim citing impediments in the form of dual pricing and allocation of vaccines at different

Jabs for all by December, says govt as Supreme Court quizzes it on vaccine policy

Apart from testing the safety and feasibility of mixing doses of different vaccines, the study will also evaluate whether mixing of doses of different vaccines help boost immune response to the virus.